Company Overview of Interface Biologics, Inc.
Interface Biologics, Inc. develops transformative biomedical polymer technology to improve the safety and effectiveness of implantable medical devices. The company’s technology focuses on anti-thrombogenic additives and programmable combination drug delivery devices. It provides Endexo technology for blood contacting medical devices that address thrombosis problems; Epidel anti-infective polymers that allow for pharmaceuticals to be integrated directly into medical devices; and Kinesyx bioactive surface pacifying oligomers. The company was founded in 2001 and is based in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2001
Key Executives for Interface Biologics, Inc.
Interface Biologics, Inc. Key Developments
Similar Private Companies By Industry
|2007262 Ontario, Inc.||Americas|
|2056273 Ontario, Inc.||Americas|
|AB BioPharma Inc.||Americas|
|AbCelex Technologies Inc.||Americas|
|AbCellera Biologics Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Interface Biologics, Inc., please visit www.interfacebiologics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.